Guest guest Posted April 29, 2011 Report Share Posted April 29, 2011 Merck's Big Day: A Share Buyback and FDA Panel Approval From the PharmaLive.com News Archive - Apr. 28, 2011 Merck & Co., said yesterday morning that it would spend $5 billion to buyback shares. Then, in the afternoon, it won a recommendation from an FDA advisory panel for its highly-anticipated hepatitis C drug. The FDA advisory panel voted 18-0 to recommend boceprevir, which will have the brand name Victrelis, as a more effective treatment than those available at the moment. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 29, 2011 Report Share Posted April 29, 2011 Merck's Big Day: A Share Buyback and FDA Panel Approval From the PharmaLive.com News Archive - Apr. 28, 2011 Merck & Co., said yesterday morning that it would spend $5 billion to buyback shares. Then, in the afternoon, it won a recommendation from an FDA advisory panel for its highly-anticipated hepatitis C drug. The FDA advisory panel voted 18-0 to recommend boceprevir, which will have the brand name Victrelis, as a more effective treatment than those available at the moment. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.